Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 496 shares of the business’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total transaction of $59,068.64. Following the sale, the chief financial officer now directly owns 74,314 shares of the company’s stock, valued at $8,850,054.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08.
- On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
- On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.
- On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.
Natera Stock Performance
Shares of NTRA stock opened at $119.17 on Friday. The firm’s 50 day moving average price is $123.37 and its 200-day moving average price is $111.09. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54. The firm has a market cap of $14.74 billion, a P/E ratio of -48.64 and a beta of 1.53.
Analyst Upgrades and Downgrades
NTRA has been the subject of several research reports. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley upped their price objective on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday. Finally, BTIG Research increased their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.
Check Out Our Latest Analysis on NTRA
Institutional Investors Weigh In On Natera
A number of hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC lifted its holdings in Natera by 17.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 10,858 shares of the medical research company’s stock worth $1,378,000 after buying an additional 1,640 shares in the last quarter. Lake Street Advisors Group LLC lifted its holdings in Natera by 7.4% during the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock worth $286,000 after buying an additional 156 shares in the last quarter. HWG Holdings LP lifted its holdings in Natera by 395.8% during the 3rd quarter. HWG Holdings LP now owns 14,920 shares of the medical research company’s stock worth $1,894,000 after buying an additional 11,911 shares in the last quarter. Zweig DiMenna Associates LLC lifted its holdings in Natera by 213.0% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 242,625 shares of the medical research company’s stock worth $30,801,000 after buying an additional 165,100 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Natera by 9,755.3% during the 3rd quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after buying an additional 14,828 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.
About Natera
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
- Five stocks we like better than Natera
- Do ETFs Pay Dividends? What You Need to Know
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What does consumer price index measure?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- ESG Stocks, What Investors Should Know
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.